ApoB (apolipoprotein B) measures the number of cholesterol-carrying particles in the blood that contribute to plaque buildup in the arteries. Although a level below 90 mg/dL is commonly considered desirable on a laboratory report, the level to aim for depends on cardiovascular risk, and newer guidelines set lower goals for people at higher risk 18.
Desirable adult level
Source: Mayo Clinic Laboratories (opens in a new tab)Under 90 mg/dLUnder 0.90 g/L
Hemo optimal range
Under 60 mg/dLUnder 0.60 g/L
What is ApoB?
For most people, a cholesterol test means looking at LDL-C, the number commonly labeled "bad cholesterol." LDL-C remains an important part of cardiovascular risk assessment, but it does not capture everything. ApoB measures a different part of the same process.
Apolipoprotein B, or ApoB, is a protein found on cholesterol-carrying particles linked with plaque buildup in the arteries. These include LDL and several other potentially harmful particles, including VLDL, IDL, remnant particles, and lipoprotein(a). Each of these particles carries one ApoB molecule, so measuring ApoB gives an estimate of how many atherogenic particles are circulating in the blood 3.
Why does particle number matter? These particles enter the wall of an artery and become trapped there. Over many years, cholesterol carried inside them contributes to plaque formation and increases the risk of heart attack or stroke.
ApoB and LDL-C measure different things
The easiest distinction is that LDL-C measures cholesterol content, while ApoB reflects particle number.
LDL particles do not all carry the same amount of cholesterol. Some people have relatively few cholesterol-rich particles, while others have many cholesterol-poor particles. Their LDL-C levels could look similar even though the second group has more particles circulating through the arteries.
This mismatch is called discordance. It is common in people with elevated triglycerides, diabetes, insulin resistance, obesity, and related metabolic conditions. Research has found that when LDL-C and ApoB disagree, cardiovascular risk tends to track more closely with ApoB 2.
ApoB also has practical advantages. Laboratories measure it directly, and testing is well standardized. A 2023 review in the Journal of the American Heart Association concluded that current ApoB testing is accurate, precise, inexpensive, and available in clinical laboratories 4.
What is a normal ApoB level?
A "normal" laboratory result and a clinical treatment goal are not the same thing.
For adults, Mayo Clinic Laboratories considers an ApoB level below 90 mg/dL desirable. Levels of 90-99 mg/dL are considered above desirable, 100-119 borderline high, 120-139 high, and 140 mg/dL or higher very high 8.
Adult ApoB categories
Source: Mayo Clinic Laboratories (opens in a new tab)Desirable Under 90 mg/dLUnder 0.90 g/L
Above desirable 90–99 mg/dL0.90–0.99 g/L
Borderline high 100–119 mg/dL1.00–1.19 g/L
High 120–139 mg/dL1.20–1.39 g/L
Very high 140 or higher mg/dL1.40 or higher g/L
These ranges help interpret a lab result. They do not tell every person what ApoB level they should aim for. Someone with no known cardiovascular disease and few risk factors does not necessarily need the same level as someone who has already had a heart attack or has established atherosclerosis.
The key distinction is context. A laboratory range describes how the result is classified, while a clinical target reflects a person’s cardiovascular risk and how aggressively their care team is trying to reduce it.
What do current guidelines recommend?
The 2026 American College of Cardiology/American Heart Association dyslipidemia guideline gives ApoB a larger role than previous U.S. guidance. LDL-C and non-HDL-C remain the main treatment measures, but the new guideline includes optional ApoB goals for several risk groups 1.
The table below separates a common laboratory range from clinical goals and treatment thresholds:
| Context | ApoB target or threshold | Source |
|---|---|---|
| Common laboratory "desirable" range | <90 mg/dL | Mayo Clinic 8 |
| Lower-risk settings | <90 mg/dL | ACC/AHA 1 |
| Higher-risk settings | <70 mg/dL | ACC/AHA 1 |
| Very-high-risk ASCVD | <55 mg/dL | ACC/AHA 1 |
| Borderline-to-intermediate risk | ≥90 mg/dL treatment-intensification threshold | NLA 2 |
| High risk | ≥70 mg/dL treatment-intensification threshold | NLA 2 |
| Very high risk | ≥60 mg/dL treatment-intensification threshold | NLA 2 |
ACC/AHA = American College of Cardiology/American Heart Association. NLA = National Lipid Association. ASCVD = atherosclerotic cardiovascular disease.
The ACC/AHA goals apply to specific clinical settings. For example, the guideline lists an ApoB goal below 90 mg/dL for primary-prevention patients with a PREVENT-ASCVD risk below 10% and triglycerides of 150–499 mg/dL, as well as people with diabetes who do not have additional ASCVD risk factors. The goal drops below 70 mg/dL for higher-risk primary prevention (a PREVENT-ASCVD risk of 10% or higher) with the same triglyceride range, and for diabetes with additional risk factors. For people with very-high-risk ASCVD, the guideline includes an ApoB goal below 55 mg/dL 1.
The 2024 National Lipid Association consensus provides more specific ApoB thresholds. It suggests considering treatment intensification at 90 mg/dL for borderline-to-intermediate risk, 70 mg/dL for high risk, and 60 mg/dL for very-high risk 2. These should be viewed as clinical decision thresholds rather than laboratory definitions of "normal."
European recommendations use somewhat different numbers. The 2019 ESC/EAS guideline proposed ApoB goals below 100 mg/dL for moderate risk, 80 mg/dL for high risk, and 65 mg/dL for very-high risk 9. The 2025 ESC/EAS focused update did not replace the entire earlier guideline with a new ApoB target system, so those secondary goals remain relevant to European practice 7.
The differences do not necessarily mean that one organization has found the single correct number. They reflect differences in how professional groups translate clinical trials, population studies, and LDL-C goals into ApoB thresholds.
How do I know if I’m high risk?
ApoB targets make more sense once you know your overall cardiovascular risk. The 2026 ACC/AHA guideline uses the PREVENT-ASCVD equations for adults ages 30–79 without known cardiovascular disease or subclinical atherosclerosis. A 10-year risk below 3% is considered low, 3% to under 5% borderline, 5% to under 10% intermediate, and 10% or higher high risk 1.
Risk assessment goes beyond a calculator. A family history of premature cardiovascular disease, diabetes, elevated triglycerides, chronic kidney disease, metabolic disease, inflammatory conditions, elevated lipoprotein(a), and certain genetic findings all affect the risk discussion. A parent or sibling with ASCVD before age 55 in men or 65 in women is considered a risk-enhancing family history 1.
Coronary artery calcium, or CAC, scoring offers another way to refine risk when the answer remains unclear. CAC scanning looks for calcified plaque in the coronary arteries. The 2026 guideline supports CAC scoring beginning at age 40 in men and age 45 in women when the result would help clarify treatment decisions 1.
There is also a case for checking lipid levels early rather than waiting until middle age. The 2026 guideline supports routine adult lipid screening starting at age 19 and repeated about every five years 1. ApoB itself remains a selective test rather than a universal screening test. Someone with a strong family history, abnormal standard cholesterol results, high triglycerides, diabetes, or other metabolic risk factors has more reason to discuss ApoB testing with a clinician. A primary care clinician, preventive cardiologist, or lipid specialist can help put those results into context.
Does research suggest that lower is better?
Overall, the evidence supports a relationship between lower ApoB and lower cardiovascular risk, particularly among people already at elevated risk.
A systematic review and meta-analysis of 29 randomized trials involving 332,912 patients found that each 10 mg/dL decrease in ApoB was associated with about a 7% lower relative risk of major cardiovascular events. Cardiovascular mortality was also lower as ApoB declined. The relationship was clearest with established LDL-receptor-mediated therapies, including statins, ezetimibe, and PCSK9 inhibitors, rather than every intervention that happened to reduce ApoB 5.
A 2024 Circulation review went a step further. After examining ApoB levels achieved in major lipid-lowering trials, the authors proposed using <70 mg/dL when the corresponding LDL-C goal is <70 mg/dL and <55 mg/dL when the LDL-C goal is <55 mg/dL. These numbers are best understood as research-informed proposed targets, not universally accepted guideline goals. The same review emphasizes that inconsistent ApoB thresholds remain a barrier to routine clinical use 3.
Since publication of that review, the 2026 ACC/AHA guideline has incorporated an ApoB goal below 55 mg/dL for selected very-high-risk settings 1. This gives the lower target more clinical support, although it still does not make <55 mg/dL the right goal for everyone.
There is another limitation. Most lipid-lowering trials were designed around medications and LDL-C, not around randomly assigning patients to specific ApoB targets. We therefore have strong evidence that reducing atherogenic lipoproteins reduces cardiovascular events, but less direct evidence proving that treating to a particular ApoB number is superior to treating to LDL-C goals 23.
What can lower ApoB?
Lifestyle remains an important part of lowering atherogenic lipoproteins. A heart-healthy eating pattern emphasizes vegetables, fruits, whole grains, legumes, nuts, seeds, and other minimally processed foods 1.
Dietary fat matters. Current guidance recommends reducing saturated and trans fats and replacing them with unsaturated fats. Saturated fat is common in foods such as fatty red meat, butter, high-fat dairy products, coconut oil, and palm oil. Olive oil, nuts, seeds, avocados, and fish provide more unsaturated fats. Replacing saturated fat with unsaturated fat lowers LDL-C and reduces atherogenic lipid burden 16.
Fiber-rich foods also support a healthier lipid profile. Oats, beans, lentils, fruits, vegetables, whole grains, nuts, and seeds provide dietary fiber. Plant proteins are another option. A 2025 review discussed controlled research in which non-meat protein diets produced lower LDL-C and ApoB than diets containing comparable amounts of red or white meat 6.
Refined carbohydrates and added sugars deserve attention, especially when high ApoB occurs alongside elevated triglycerides or insulin resistance. Higher intakes of added sugar and refined grains promote triglyceride-rich lipoproteins and a more atherogenic lipid pattern 6. Fiber-rich carbohydrates such as oats, legumes, fruits, vegetables, and whole grains differ from sugary drinks, sweets, and refined grains.
Physical activity and weight management matter too. The 2026 guideline recommends at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of vigorous activity each week, plus resistance exercise on two days 1. For people with overweight or obesity and dyslipidemia, weight reduction of at least 5% improves lipid and metabolic measures 1.
Lifestyle changes do not always lower ApoB enough for someone at high cardiovascular risk. Statins remain first-line drug therapy for most people who need medication. If additional lowering is needed, treatment options include ezetimibe, bempedoic acid, and PCSK9 monoclonal antibodies. Inclisiran also lowers LDL-C and ApoB-containing particles, although cardiovascular outcome data remain under study 17. Treatment choice depends on overall risk, starting lipid levels, response, side effects, and other medical factors.
So, what should your ApoB be?
For someone reading a standard laboratory report, below 90 mg/dL is a reasonable definition of "desirable." But desirable is not the same as optimal for every person.
Someone at lower cardiovascular risk does not need the same ApoB target as someone with established cardiovascular disease. Current U.S. guidance uses goals around 90 mg/dL in selected lower-risk settings, 70 mg/dL in higher-risk settings, and 55 mg/dL for very-high-risk ASCVD 1. Other professional groups use slightly different thresholds.
The better question is not simply, "Is my ApoB normal?" It is, "Is my ApoB appropriate for my overall cardiovascular risk?"
Is there an optimal ApoB range?
No guideline sets one optimal ApoB for everyone. Goals get lower as heart risk goes up, and studies of lifelong exposure suggest that lower is better even for people without heart disease.
For people at higher risk, Europe’s goals are below 80 mg/dL at high risk and below 65 at very high risk 9. The U.S. guideline aims below 55 for people with very-high-risk ASCVD 1, and the National Lipid Association treats 60 as the point to step up treatment at very high risk 2.
For people without heart disease, the case for aiming low comes from studies of lifelong exposure. Across more than 2 million people, the risk of heart and artery disease rose steadily with exposure to LDL, and the effect appeared to grow with the number of years it lasted 10. In a genetic study of about 655,000 people, each 10 mg/dL lower ApoB was linked with about 23% lower coronary heart disease risk, whether the genes lowered triglycerides or LDL cholesterol 11.
Hemo’s ranges follow those goals. In the app, ApoB under 80 mg/dL shows as normal and under 60 as optimal, both stricter than the lab’s desirable level of 90 8.
Strength of evidence: guideline goals for higher-risk groups, plus strong genetic evidence that lower is better over a lifetime. No trial has tested 60 as a target for everyone, and a result above it isn’t a diagnosis. Whether it’s worth lowering further depends on your overall risk, which is a decision to make with your doctor 1.
Related biomarkers
- LDL cholesterol: measures the cholesterol carried in LDL particles, while ApoB reflects how many particles there are 3.
- Non-HDL cholesterol: total cholesterol minus HDL, one of the two main treatment measures in the 2026 guideline 1.
- Lp(a): an ApoB-carrying particle that the 2026 guideline recommends measuring at least once in adulthood 1.
- Triglycerides: ApoB and LDL-C disagree most often when triglycerides are high 12.
Tracking ApoB over time with Hemo
ApoB is most useful read next to your LDL, non-HDL, and triglycerides, and over time as your diet or treatment changes 1. Hemo keeps your lipid results in one place so you can see ApoB alongside the rest of your panel and bring that history to your doctor.
Track your results with Hemo: tryhemo.com
FAQs
Do I need to fast for an ApoB test?
Usually not. The 2026 ACC/AHA guideline notes that ApoB measurement is standardized and unaffected by fasting 1. Follow your provider’s instructions, since other tests on the same draw may need fasting.
Is ApoB better than LDL cholesterol?
It measures something different. LDL-C reflects cholesterol content, while ApoB reflects particle number, and when the two disagree, cardiovascular risk tends to track more closely with ApoB 23. LDL-C and non-HDL-C remain the main treatment measures in the 2026 U.S. guideline 1.
What ApoB level should I aim for?
It depends on your overall cardiovascular risk. Below 90 mg/dL is the common laboratory definition of desirable 8, and the 2026 ACC/AHA guideline sets lower goals of below 70 or below 55 mg/dL for higher-risk groups 1.
Sources
Checked Nov 18, 2026.
- Blumenthal RS et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia — Circulation, 2026
- Soffer DE et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association — J Clin Lipidol, 2024
- De Oliveira-Gomes D et al. Apolipoprotein B: bridging the gap between evidence and clinical practice — Circulation (PMC), 2024;150:62–79
- Contois JH, Langlois MR, Cobbaert C, Sniderman AD. Standardization of apolipoprotein B, LDL-cholesterol, and non-HDL-cholesterol — J Am Heart Assoc, 2023
- Khan SU et al. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: systematic review and meta-analysis of trials — Eur J Prev Cardiol (PMC), 2020;27:1255–1268
- Kim S, Shin M-J, Krauss RM. Dietary management of atherogenic dyslipidemia — Curr Atheroscler Rep, 2025;27:93
- Mach F et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias, considered with the 2025 ESC/EAS focused update — European Atherosclerosis Society
- Apolipoprotein B, serum — Mayo Clinic Laboratories
- Mach F et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk — Eur Heart J (PubMed), 2020;41:111–188
- Ference BA et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel — Eur Heart J (PubMed), 2017;38:2459–2472
- Ference BA et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease — JAMA (PubMed), 2019;321:364–373
Not medical advice
This page is for general education and doesn’t replace advice from your doctor. Talk to your doctor about your results and what they mean for you.
